

**PATENT**

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
PATENT EXAMINING OPERATION**

Applicant(s): Nobuto YAMAMOTO

Serial No: 09/826,463

Group Art Unit: 1647

Filed: April 5, 2001

Examiner: David S. ROMEO

Att. Docket No.: Y1004/20017

Confirmation No.: 2419

For: PREPARATION OF POTENT MACROPHAGE ACTIVATING FACTORS  
DERIVED FROM CLONED VITAMIN D BINDING PROTEIN AND ITS DOMAIN  
AND THEIR THERAPEUTIC USAGE FOR CANCER, HIV-INFECTION AND  
OSTEOPETROSIS

**IDS CERTIFICATION STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR §1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the concurrently filed Form PTO/SB/08a. Unless otherwise indicated herein, one copy of each reference is submitted herewith. No copies of U.S. patents or U.S. patent application publications are submitted herewith. 37 CFR § 1.98(a)(2)(ii). It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. No representation is made that the reference(s) is/are prior art with respect to this application.

This Information Disclosure Statement is being filed after the period specified in 37 CFR § 1.97(c), but on or before payment of the Issue Fee. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. Authorization to charge the additional fee under 37 CFR §1.17(p) is granted in the concurrently filed Fee Transmittal Form.

Application No. 09/826,463

IDS Certification Statement dated December 10, 2007

A concise explanation of the relevance of the non-English language reference(s) appears in the Appendix submitted herewith.


Respectfully submitted,

CAESAR, RIVISE, BERNSTEIN,  
COHEN & POKOTILOW, LTD.

December 10, 2007

Please charge or credit our Account  
No. 03-0075 as necessary to effect  
entry and/or ensure consideration of  
this submission.

By

  
\_\_\_\_\_  
Joseph F. Murphy  
Registration No. 58,313  
Customer No. 03000  
(215) 567-2010  
Attorneys for Applicant(s)

### **Appendix to IDS Certification Statement**

**"Shi-Seikagaku Jikken Kohza, Proteins VI: Synthesis and Expression" published by Tokyo Kagaku Doujin, June 15, 1992, p. 291-311.**

The Shi-Seikagaku Jikken Kohza reference teaches that baculovirus-based protein expression systems are advantageous in that the expressed protein can be modified by glycosylation.